Clinical study of Bufei Huoxue Capsules in treatment of mild and moderate novel coronavirus pneumonia
Objective To observe the efficacy of Bufei Huoxue Capsules in treatment of mild and moderate novel coronavirus pneumonia.Methods A total of 160 patients with mild and moderate novel coronavirus pneumonia admitted to Henan Provincial Hospital of Traditional Chinese Medicine from December 2022 to April 2023 were selected and randomly divided into control group(80 cases)and treatment group(80 cases)according to random number table method.Patients in the control group were given conventional drug treatment.Patients in the treatment group were po administered with Bufei Huoxue Capsules on the basis of control group,4 capsules/time,3 times daily.Both groups were treated continuously for 2 weeks.The clinical efficacy,chest CT imaging improvement,nucleic acid negative time,symptom duration and hospital stay of two groups were observed,and the changes of inflammation index,coagulation function index,pneumonia severity(PSI)score,CURB-65 score and clinical pulmonary infection(CPIS)score before and after treatment were compared between the two groups.Results After treatment,the total effective rate of treatment group was 83.75%,which was significantly higher than that of control group(43.75%,P<0.05).There was no significant difference in the improvement of chest CT between treatment group and control group.Compared with the control group,the time of nucleic acid turning negative,symptom duration and hospitalization days in treatment group were significantly reduced(P<0.05).After treatment,C-reactive protein(CRP)levels were decreased in both groups,but leukocyte(WBC),neutrophil percentage(NEUT%)and lymphocyte percentage(LYMPH%)levels were increased in both groups(P<0.05).After treatment,CRP levels in treatment group were lower than those in control group,WBC,NEUT%and LYMPH%levels were higher than those in control group(P<0.05).After treatment,the prothrombin time(PT),activated partial thromboplastin time(APTT)and D-dimer were all decreased,but the thrombin time(TT)level was increased in both groups(P<0.05).After treatment,the regulation effect of coagulation function index in treatment group was increased significantly(P<0.05).After treatment,PSI score,CURB-65 score and CPIS score in both groups were significantly decreased compared with before treatment(P<0.05).After treatment,the PSI score,CURB-65 score and CPIS score of treatment group were lower than those of control group(P<0.05).Conclusion Bufei Huoxue Capsules has good clinical efficacy in treatment of novel coronavirus pneumonia,and can inhibit inflammation,correct blood hypercoagulability,shorten the negative nucleic acid time and hospitalization days,which can relieve clinical symptoms of patients with high safety.
NETL
NSTL
万方数据
